Three new products set to become pharmacy only medicines
The latest round of proposed reclassifications from
POM to P will add new treatments to the pharmacists’ armamentarium of
products with which to treat diarrhoea, sore throat and fungal skin infections.
Consultation letter MLX274, issued by the Medicines
Control Agency, proposes the reclassification of co-phenotrope tablets
(diphenoxylate hydrochloride 2.5mg with atropine sulphate 0.025mg, Lomotil)
as a pharmacy medicine. The expected indication is as a short-term adjunct
to appropriate rehydration treatment of diarrhoea in people aged 16 years
and over. There will be a maximum daily dose of 10 tablets and a maximum
pack size of 20 tablets.
Flurbiprofen 8.75mg lozenges are to become a pharmacy
medicine indicated for the relief of sore throat, with a maximum pack
size of 16 lozenges and a maximum daily dose of 5 lozenges.
The third proposed change will see 30g packs of
terbinafine 1 per cent gel made P for the treatment of tinea pedis (athlete’s
foot), tinea cruris (jock itch) and tinea corporis (ringworm).
In addition, ropinirole hydrochloride and dolasetron
mesilate, which are POM by reason of their marketing authorisations, are
to be added to the POM Order.
A Statutory Instrument to implement the changes
is to be laid before Parliament during December. Comments on the changes
can be set to Tricia Griffiths, Room 14–110, MCA, Market Towers, 1 Nine
Elms Lane, London SW8 5NQ until 18 October.
Back to Top
|
